openPR Logo
Press release

Asia-Pacific Conjugate Vaccine Market Projected to Reach US$ 66.61 Billion at 23.5% CAGR Till 2023 | Key Players – GlaxoSmithKline, Pfizer, Merck, Novartis

01-08-2019 04:37 AM CET | Health & Medicine

Press release from: Business Industry Reports

Asia-Pacific Conjugate Vaccine Market

Asia-Pacific Conjugate Vaccine Market

A fresh report has been added to the wide database of Business Industry Reports. The research study is titled “Conjugate Vaccine Market” by Manufacturers, Countries, Type and Application, Forecast to 2023 which provides important data about the production, consumption, revenue and company profiles for key industry participants.

Asia-Pacific Conjugate Vaccine Market Synopsis:

The conjugate vaccines market in Asia-Pacific is expected to expand at a CAGR of 23.5%, leading to a revenue of USD 66.61 Bn by 2023. By volume, it is anticipated to reach 6,883.55 Million units by 2023, expanding at a CAGR of 21.87%.

Get Free Sample Study Papers of “Asia-Pacific Conjugate Vaccine Market” @ https://www.businessindustryreports.com/sample-request/122658 .

Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. Asia Pacific is the fastest growing market for conjugate vaccines. The Asia Pacific has a growing market owing to improvement and advancements in medical science. Awareness about availability of higher number of vaccines as compared to before are major driving factors for the growth of this market. The primary indicators of the potential for the vaccine market are the geriatric population in Asia and its growth in some countries such as India and China.

Asia-Pacific Conjugate Vaccine Market can be segmented on the Basis of By disease indication, End user and Countries. On the Basis of disease indication Asia-Pacific Conjugate Vaccine Market can be sub segmented into Pneumococcal, Haemophilus influenza type B, Diphtheria-tetanus-pertussis, Meningococcal, Others. The diphtheria tetanus pertussis segment of the conjugate vaccine market expanded in 2016 due to its high prevalence and highly contagious nature of the respiratory tract infection.

Based on countries, Countries with high populations such as China and India, serve as major target areas for such vaccines, and the introduction of these vaccines would ensure a disease-free society.

Complete report on Asia-Pacific Conjugate Vaccine Market spread across 90 Pages and No. of Table of contents. Buy Research at https://www.businessindustryreports.com/buy-now/122658/single .

The Market is segmented and projected on the basis of major key player’s:

1 GlaxoSmithKline

2 Pfizer Inc

3 Merck

4 Novartis

5 Sanofi Pasteur

Market segment by Regions/Countries, this report covers:

1 China

2 India

3 Japan

4 South Korea

Request a Discount on standard prices of this premium report at https://www.businessindustryreports.com/check-discount/122658 .

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Key Questions Answered in this Report:

1 What will the market size be in 2023?

2 What is driving this market??

3 What are the challenges to market growth?

4 Who are the key players in Conjugate Vaccine Market?

5 What are the market opportunities and threats faced by the key players?

TABLE OF CONTENTS

1 Executive summary

2 Market overview

3 Asia-Pacific major segment overview - by disease indication

4 Asia-Pacific major segment overview - by end user

5 China – by disease indication

6 China – by end user

7 India – by disease indication

8 India – by end user

9 Japan – by disease indication

10 Japan – by end user

11 South Korea – by disease indication

12 South Korea – by end user

13 Competitive landscape

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Asia-Pacific Conjugate Vaccine Market Projected to Reach US$ 66.61 Billion at 23.5% CAGR Till 2023 | Key Players – GlaxoSmithKline, Pfizer, Merck, Novartis here

News-ID: 1476950 • Views: 153

More Releases from Business Industry Reports

2020-2025 Neoantigen Targeted Therapies Market to witness astonishing growth wit …
Global Neoantigen Targeted Therapies Market Synopsis: The report covers a forecast and an analysis of the Neoantigen Targeted Therapies Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Neoantigen Targeted Therapies Market along with the impact they have
Outstanding Scope of Nasojejunal Tube Market is Estimated to Grow Incredible CAG …
Overview of Global Nasojejunal Tube Market: This report provides in-depth study of “Global Nasojejunal Tube Market 2020” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Nasojejunal Tube Market report also provides an in-depth survey of key players in the market organization. The 'Global Nasojejunal Tube Industry, Market Research Report' is a professional and in-depth study on the current state of the global Nasojejunal Tube Market with a
Huge Investment in mTOR Inhibitors Market Expected to Witness the Highest Growth …
Global mTOR Inhibitors Market Synopsis: The exclusive research report on the Global mTOR Inhibitors Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global mTOR Inhibitors Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. According to the market research study, Mammalian Target Of Rapamycin (mTOR) is
SWOT Analysis of mRNA Treatment Market Excessive Growth Opportunities Estimated …
The exclusive research report on the Global mRNA Treatment Market 2020 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global mRNA Treatment Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. Overview of Global mRNA Treatment Market: This report studies the Global mRNA Treatment Market over the forecast

All 5 Releases


More Releases for Asia

RAMPF Korea – Producing in Asia for Asia
Joint Venture for the Asian markets – The international RAMPF Group has realigned the cooperation with its long-standing partner Orient Dosiertechnik from Korea with the founding of RAMPF Korea Co., Ltd. The new company based in Hwaseong City is developing and producing mixing and dispensing systems specifically for the Asian markets. Within the framework of the new joint venture based in Hwaseong City, mixing and dispensing systems are being developed and
LIXIL Asia Presents Asia Pacific Property Awards
Through its power brands GROHE and American Standard, LIXIL Asia signs a three-year deal to become the Headline Sponsor of the Asia Pacific Property Awards from 2019 until 2022. 23rd January 2019: The International Property Awards, first established in 1993, are open to residential and commercial property professionals from around the globe. They celebrate the highest levels of achievement by companies operating within the architecture, interior design, real estate and property
MES: Expansion in Asia
Berlin, November 24, 2014: Model Engineering Solutions (MES), the Berlin-based specialist for model-based software development, has significantly expanded its business in Asia. In recent years, MES has built up a network of local partners in Japan, Korea, China, and India in order to benefit from the growing market and increasing interest in model-based development and ISO 26262 in Asia. Asia: Driving force in the automotive industry The automotive industry continues
Undersea Defence Technology Asia, UDT Asia 2011
Latest Military Diving Technologies featured in UDT Asia Equipping Asia’s navies with the latest diving technology for asymmetric warfare and operations SINGAPORE, 17 October 2011 - Naval diving and underwater special operations is a field that is seeing increased attention and investment amongst navies in Asia. Units such as the Indonesian Navy‟s KOPASKA, the Republic of Singapore Navy‟s Naval Diving Unit (NDU), the Royal Malaysian Navy‟s PASKAL are increasingly utilising specialised equipment for conducting
UDT Asia 2011
Clarion Events hosts the Undersea Defence Technology (UDT) Asia 2011 conference and exhibition to bring senior naval and industry personnel together to cover underwater developments in the region Singapore, May 30 – Clarion Events is hosting UDT Asia on 30 November – 1 December 2011. The event brings together the undersea defence community in Asia, featuring top regional naval speakers, who will be addressing the latest underwater requirements for Asian navies. According
eltherm goes Asia
Finally all preparations are finished and the new subsidiary of eltherm GmbH, eltherm Asia Pacific Pte Ltd has commenced operations in Singapore on 1st April 2010. To celebrate the starting shot, an opening celebration was held in the afternoon of 28th July in the office premises followed by a get together dinner and drinks in the evening at a pub. A total of 62 guests attended the event with the